Nimesil (Nimesulide)

Nimesulide selectively blocks the cyclooxygenase‑2 (COX‑2) enzyme, which is responsible for producing prostaglandins that mediate inflammation, pain, and fever. By reducing prostaglandin synthesis at sites of injury or infection, nimesulide diminishes the sensory signals that cause pain and lowers the hypothalamic set‑point that raises body temperature.

The appropriate dose of Nimesil is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and renal or hepatic function. The prescriber will specify the exact volume of oral suspension to be taken and the frequency of administration, which should be followed exactly as instructed.

Nimesil is classified as pregnancy category X, meaning it is contraindicated in all stages of pregnancy due to the risk of fetal harm. It is also not recommended for breastfeeding mothers because nimesulide can be excreted in breast milk and may affect the infant. Alternative therapies should be considered.

To request Nimesil, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. After verification, the sales team provides pricing, availability, shipping details (including any temperature requirements), and assists with import documentation.

Nimesulide offers relatively selective COX‑2 inhibition, which may result in a lower incidence of gastrointestinal irritation compared with non‑selective NSAIDs like ibuprofen. However, it carries a higher risk of liver toxicity, especially with prolonged use. Choice of agent should consider the patient’s hepatic profile, required duration of therapy, and individual risk factors.

Nimesil oral suspension should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original container, protect it from moisture, direct sunlight, and extreme temperature fluctuations. Do not freeze the suspension, and discard any product that appears discolored or has an unusual odor.

Nimesil is supplied as an oral suspension that is measured with a calibrated dosing spoon or syringe. The prescribed volume is taken by mouth, usually with or without food, as directed by the healthcare provider. Patients should shake the bottle gently before each use to ensure uniform drug distribution.

The most serious risks include hepatotoxicity, which can manifest as elevated liver enzymes or severe liver injury, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Additional concerns are renal impairment, especially in patients with pre‑existing kidney disease, and potential bleeding complications when combined with anticoagulants.

Nimesil should be avoided in individuals with known hypersensitivity to nimesulide or any NSAID, pregnant women (category X), patients with active peptic ulcer disease, severe hepatic or renal impairment, and those taking anticoagulants, other NSAIDs, or lithium without close medical supervision.